Kymera Therapeutics, Inc.
KYMRNasdaq
$115.77
↑ +1.6%Jul 17 close · end-of-day
Price
1Y↑ +154.4%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$11.3B
Enterprise Value
$10.6B
P/E
—
P/S
219.4
P/B
7.3
EV/EBITDA
—
PEG
—
FCF Yield
-2.2%
Dividend Yield
—
Revenue (TTM)
$51.5M
Net Income (TTM)
$307.7M
Free Cash Flow (TTM)
-$244.0M
Gross Margin
—
Operating Margin
-697.7%
Net Margin
597.8%
ROE
20.0%
ROIC
-31.9%
Debt / Equity
—
Net Cash
$650.9M
Return 1Y
+149.8%
Company profile
Kymera Therapeutics, Inc. focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases. IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the. treatment of hematologic malignancies and solid tumors.
- CEO
- Nello Mainolfi
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 170
- Headquarters
- Massachusetts
- Website
- kymeratx.com
Management & directors
- Mainolfi NelloChief Executive Officer
- Goodman NoahChief Business Officer
- Jacobs Bruce N.Chief Financial Officer
- Chadwick Jeremy GChief Operating Officer
- Gollob JaredChief Medical Officer
- Adams BrianChief Legal Officer
Roles derived from SEC Form 4 filings.
Earnings
KYMR Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$34.4M↑ +55.5%
Diluted EPS-$0.71↓ -13.4%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $34.0M | $72.8M | $46.8M | $78.6M | $47.1M | $39.2M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$46.3M | -$100.5M | -$161.3M | -$165.5M | -$261.6M | -$349.4M |
| Net income | -$45.6M | $100.2M | $154.8M | $147.0M | $223.9M | $311.4M |
| Diluted EPS | -$3.15 | -$2.09 | -$2.87 | -$2.52 | -$2.98 | -$3.69 |
| Operating cash flow | $88.1M | -$128.9M | -$153.1M | -$102.8M | -$194.5M | -$232.9M |
| Free cash flow | $79.0M | -$130.5M | -$155.9M | -$137.3M | -$207.3M | -$234.3M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -136.1% | -138.0% | -344.4% | -210.6% | -555.8% | -891.1% |
| Net margin | -134.0% | 137.6% | 330.6% | 187.0% | 475.6% | 794.0% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $25.6M | $3.7M | $7.4M | $22.1M | $11.5M | $2.8M | $2.9M | $34.4M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$50.9M | -$72.1M | -$80.8M | -$74.4M | -$84.6M | -$92.5M | -$97.9M | -$84.2M |
| Net income | -$42.1M | -$62.5M | $377.0M | -$65.6M | -$76.6M | -$82.2M | $535.7M | -$69.2M |
| Diluted EPS | -$0.58 | -$0.82 | -$0.89 | -$0.82 | -$0.95 | -$0.94 | -$0.98 | -$0.71 |
| Operating cash flow | -$42.9M | -$50.2M | -$61.8M | -$79.2M | -$59.9M | -$27.1M | -$66.7M | -$88.8M |
| Free cash flow | -$47.6M | -$50.4M | -$62.7M | -$79.6M | -$60.6M | -$27.3M | -$66.9M | -$89.3M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -198.5% | -1927.9% | -1092.2% | -336.8% | -736.8% | -3347.4% | -3409.8% | -244.9% |
| Net margin | -164.0% | -1670.3% | 5098.2% | -296.7% | -667.6% | -2973.0% | 18659.7% | -201.5% |
Company news
Jul 13, 2026
Jul 9, 2026
Jul 3, 2026
- 17d agoAlkami Technology, Diebold Nixdorf, and 3 More Stocks See Action From Activist Investors.finance.yahoo.com
- 17d agoKymera Therapeutics (KYMR) Stock Gets Fair Value Bump After KT 621 Timeline Shiftfinance.yahoo.com
- 17d agoHow Accelerated KT-621 Trial, Index Additions, and New Chair Will Impact Kymera Therapeutics (KYMR) Investorsfinance.yahoo.com
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-07 | Mainolfi Nello· Chief Executive Officer | Sale | 50,000 | $119.00 | $6.0M | filing |
| 2026-07-07 | Mainolfi Nello· Chief Executive Officer | Option exercise | 50,000 | $2.08 | $104,000.00 | filing |
| 2026-07-01 | Mainolfi Nello· Chief Executive Officer | Sale | 44,050 | $115.69 | $5.1M | filing |
| 2026-07-01 | Mainolfi Nello· Chief Executive Officer | Sale | 24,105 | $114.96 | $2.8M | filing |
| 2026-07-01 | Mainolfi Nello· Chief Executive Officer | Sale | 6,626 | $113.98 | $755,203.65 | filing |
| 2026-07-01 | Mainolfi Nello· Chief Executive Officer | Sale | 3,336 | $116.56 | $388,840.82 | filing |
| 2026-07-01 | Goodman Noah· Chief Business Officer | Sale | 3,389 | $114.29 | $387,328.81 | filing |
| 2026-07-01 | Mainolfi Nello· Chief Executive Officer | Sale | 1,883 | $112.80 | $212,411.06 | filing |
| 2026-07-01 | Mainolfi Nello· Chief Executive Officer | Option exercise | 80,000 | $2.08 | $166,400.00 | filing |
| 2026-06-30 | Jacobs Bruce N.· Chief Financial Officer | Sale | 51,375 | $114.77 | $5.9M | filing |
| 2026-06-30 | Jacobs Bruce N.· Chief Financial Officer | Sale | 7,971 | $115.82 | $923,178.10 | filing |
| 2026-06-30 | Jacobs Bruce N.· Chief Financial Officer | Sale | 6,153 | $116.99 | $719,862.24 | filing |
| 2026-06-30 | Jacobs Bruce N.· Chief Financial Officer | Sale | 4,110 | $114.19 | $469,310.63 | filing |
| 2026-06-30 | Jacobs Bruce N.· Chief Financial Officer | Sale | 3,200 | $117.70 | $376,649.28 | filing |
| 2026-06-30 | Jacobs Bruce N.· Chief Financial Officer | Option exercise | 61,378 | $5.33 | $327,144.74 | filing |
| 2026-06-30 | Jacobs Bruce N.· Chief Financial Officer | Sale | 1,700 | $111.57 | $189,664.07 | filing |
| 2026-06-30 | Jacobs Bruce N.· Chief Financial Officer | Sale | 1,500 | $110.54 | $165,809.55 | filing |
| 2026-06-30 | Jacobs Bruce N.· Chief Financial Officer | Sale | 1,100 | $112.79 | $124,066.91 | filing |
| 2026-06-29 | Booth Bruce | Sale | 19,419 | $107.76 | $2.1M | filing |
| 2026-06-29 | Booth Bruce | Sale | 19,093 | $107.76 | $2.1M | filing |
| 2026-06-29 | Booth Bruce | Sale | 14,798 | $106.63 | $1.6M | filing |
| 2026-06-29 | Booth Bruce | Sale | 14,613 | $106.63 | $1.6M | filing |
| 2026-06-29 | Booth Bruce | Sale | 10,848 | $108.28 | $1.2M | filing |
| 2026-06-29 | Booth Bruce | Sale | 10,658 | $108.28 | $1.2M | filing |
| 2026-06-29 | Booth Bruce | Sale | 7,968 | $109.75 | $874,488.00 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.